Because of our inability to isolate rubella virus from peripheral blood lymphocytes from patients with chronic symptoms after rubella immunization we performed a series of experiments with cord blood mononuclearcells (CBL) to determine whether and to what extent these cells supported the growth of rubella virus in vitro. CBL were stimulated with phytohemagglutinin for h, washed, and inoculated with 1000 tissue culture 50% infectiondose of rubellavirus and placedin RPMI 1640 medium with 10% fetal bovine serum and IL-2.Approximately every 9 d the volumewas halved,and new CBLwere added. Aliquotsat 2-to 9-d intervals were obtained and quantitatively cultured in Arthralgias are common in postpubertal women after immunization with rubella vaccine (1) . Infrequently chronic or recurrent arthralgias, sometimes with arthritis and/or varied neurologic manifestations have been noted in vaccinees (2) . Several studies have suggested that these chronic illnesses are the result of persistent rubella vaccine virus infection involving mononuclear leukocytes (3) (4) (5) . Because of these reports our group studied a number of adults with chronic symptoms after rubella immunization, and we were unable to isolate rubella virus from their peripheral blood lymphocytes (6) .
Because of our inability to duplicate the findings of others, we have attempted to infect CBL in vitro with RA 27/3 vaccine virus. The purpose of the presently reported studi es was to determine under controlled conditions whether rubell a vaccine virus would persist and grow in immunologically naive mononuclear cells. Abbreviations CBL, cord blood lymphocyte TCID so, 50% tissue culture infective dose centrifugation with Lymphoprep (Nycomed Pharmaceuticals, Oslo, Norway) and resuspended in RPMI 1640 medium (Irvine Scientific, Santa Ana , CA) with phytohemagglutinin (Difco , Detroit, MI) for 48-72 h at 36°C. After incubation, cells were washed twice in phosphate-buffered saline and resuspended in 2 mL of RPMI medium. Viable cells were counted using trypan blue exclusion, and two pellets were prepared with 5 X 10 6 cells in each.
METHODS

Preparation of
Experimental design. An outine of the experimental design is presented in Figure 1 . The rubella vaccine virus was Meruvax II (Merck, Sharp & Dohme, West Point , PA). Penicillin/ streptomycinlFungizone and fetal bovine serum were purchased from Irvine Scientific, Santa Ana, CA, and IL-2 was obtained from Boehringer Mannheim, Indianapolis, IN.
Viral cultures. Cultures were performed in African green monkey tissue culture cells obtained from Bio Whittaker, Walkersville, M.D.. Aliquots (0.5 mL) for culture were diluted from 10 0 to 10-3 and 0.5 mL of each dilution were inoculated into singl e African green monkey kidney tissu e culture tubes.
In som e experiments dilutions were extended to 10-4 and duplicate African green monkey kidney tissue culture tubes were used. Cultures were incubated for 7 d at 36°C and the presence of rubella virus determined by challenge with a 100 TCID so On day 0 and at varied int ervals 0.5 ml removed for viral culture.
0.5 ml of diluent containing 1000 TCID50
of RA 27/3 vaccine virus incubat ed at 36 0 C for 2 hours.
Same as 1.
CBLs resuspended in 0.5 mI of RPMI medium and incubat ed at 36 0 C for 2 hours.
Eleven experiments were performed, and the results are summarized in Table 1 . Rubella virus persisted in CBL longer than in controls in 7 of 11 experiments (experiments 4-10) and in three instances there was evidence of productive infection (experiments 6-8). In two experiments (1 and 11) infection did not occur and in two others (experiments 2 and 3) the studies were terminated without the addition of new CBL.
The longitudinal events in experiment 6 are presented in Figure 2 . In this experiment the virus titer increased lOO-fold and productive infection persisted for 145 d. Similar findings were noted in experiments 7 and 8.
DISCUSSION
After the report of the isolation of rubella virus in 1962 (7) it was found that infants with congenital rubella had prolonged infections (7) (8) (9) (10) (11) (12) (13) (14) ; viremia occurred and leukocytes were found to be infected. In contrast, persistent infection was not noted in postnatal illnesses due to rubella virus. In 1965 Mellman et al. (15) noted that leukocytes from a seronegative woman had only a limited ability to support the replication of rubella virus when compared with other viruses such as measles, echovirus 9, and herpes simplex (15) .
In recent years there has been a renewed interest in the possibility of persistent rubella virus infection (2) due to a series of publications relating arthritic and other chronic symptoms in previously vaccinated adults with persistent rubella virus in peripheral blood lymphocytes of the affected patients (3) (4) (5) . These studies led us to search for persistent rubella virus infections in peripheral blood lymphocytes from subjects with infective dose of echovirus 11 (7) . All cultures were blind passed once and after 7 d of incubation were rechallenged with echovirus 11. Presence of rubella virus infection was assumed if typical enteroviral cytopathic effect did not occur.
When rubella virus was recovered from CBL for a longer duration of time than from the controls, we considered this evidence of virus persistence. Virus growth and productive infection was considered to have occurred if the titer of virus chronic illnesses following immunization (6). Although we were able to isolate virus from two vaccinees shortly after immunization and from one patient with natural infection, we were unable to isolate virus from any patients with chronic illnesses. In addition, since we also isolated rubella virus from the pharynx and from polymorphonuclear leukocytes of recent vaccinees we questioned the tropism of rubella virus for lymphocytes and therefore initiated the present study.
As noted in Table 1 and Figure 2 , productive rubella virus infection was demonstrated in three of 11 experiments.
Since rubella virus can infect and replicate in CBL in vitro, it is possible that persistent rubella virus infection of peripheral blood lymphocytes can occur. Therefore in spite of our previous negative studies in patients with chronic illnesses it seems reasonable to prospectively study adult vaccinees who develop arthralgias and other symptoms for persistent rubella virus infections .
